

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Elizabeth Spar on April 26, 2011.

The application has been amended as follows:

Claims 4, 5, 11-17 and 23-47 are cancelled without prejudice.

Claims 1, 3, 6-10, 18-22, 48 and 49 are pending.

Claim 1. An isolated peptide [[agent]] that specifically binds focal adhesion kinase and induces apoptosis in a cell that expresses focal adhesion kinase; wherein said peptide [[agent]] consists of the amino acid sequence of SEQ ID NO: 3.

Claim 3. ~~The agent of claim 1, wherein the agent is a chimeric molecule that consists of the amino acid sequence of SEQ ID NO: 3~~ A chimeric molecule that comprises the peptide of claim 1 and a membrane permeabilization domain.

Claim 6. A composition comprising an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 3, or a variant thereof, wherein said variant is at least 90% identical

[[homologous]] to SEQ ID NO: 3, wherein the peptide or variant [[composition]] binds focal adhesion kinase (FAK), induces [[and modulates]] cellular apoptosis[[],] and inhibits cell motility [[and metastasis]].

Claim 7. A [[The]] composition ~~of claim 6 wherein the composition further comprises a cellular permeabilization domain comprising the chimeric molecule of claim 3.~~

Claim 9. The composition of claim 6, wherein the peptide or variant induces apoptosis [[is induced]] in a tumor.

Claim 10. The composition of claim 6, wherein the peptide or variant inhibits cell motility [[is inhibited]].

Claim 18. A composition comprising a chimeric molecule [[consisting of]] comprising a targeting domain and the peptide of claim 1 consisting of amino acid sequence of SEQ ID NO: 3 or a variant thereof, wherein said variant is at least 90% identical to SEQ ID NO: 3, wherein the chimeric molecule binds focal adhesion kinase.

Claim 21. The composition of claim 18, wherein the targeting domain is an antibody that binds [[specific for]] a tumor antigen.

Claim 22. The composition of claim 21, wherein the tumor antigen antigens ~~comprise is selected from the group consisting of~~ HER-2/neu; intestinal carboxyl esterase (liver, intestine, kidney); alpha-fetoprotein (liver); M-CSF (liver, kidney); MUC1 (glandular epithelia); p53; PRAME (testis, ovary, endometrium, adrenals); PSMA (prostate, CNS, liver); RAGE-1 (retina); RU2AS (testis, kidney, bladder); survivin; Telomerase; WT1 (testis, ovary, bone marrow, spleen); and CA125 (ovarian).

Claim 48. A composition comprising an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 3, wherein the composition binds focal adhesion kinase (FAK), and modulates cellular apoptosis, cell motility and cell metastasis.

Claim 49. A composition comprising a chimeric molecule, consisting of amino acid sequence SEQ ID NO: 3 wherein the chimeric molecule comprises the peptide of claim 1, and a targeting domain.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne Holleran, whose telephone number is (571) 272-0833. The examiner can normally be reached on Monday through Friday from 9:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Misook Yu, can be reached on (571) 272-0839. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. The faxing of such papers must conform to the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The Official Fax number for Group 1600 is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free).

Anne L. Holleran
Patent Examiner

/Alana M Harris, Ph.D./
Primary Examiner, Art Unit 1643